tiprankstipranks
MyMD Pharmaceuticals (GB:0A8D)
LSE:0A8D

MyMD Pharmaceuticals (0A8D) Ownership - Who Owns MyMD Pharmaceuticals?

1 Followers

Recent Insider Trading Activity

Date
Name
Activity
Value
Aug 24, 2023Bought$166500
Aug 18, 2023Bought$28000

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
6,000,538Insider278.11%15,373,378
2,256,863Insider104.60%5,782,083
1,396,993Institution64.75%3,579,096
1,013,392Insider46.97%2,596,310
967,616Insider44.85%2,479,032
478,150Insider22.16%1,225,020
478,150Insider22.16%1,225,020
405,732Insider18.80%1,039,485
400,000Insider18.54%1,024,800
383,957Insider17.80%983,698

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
1,396,993Institution64.75%3,579,096
26,030Institution1.21%66,689
25,990Institution1.20%66,586
13,965Institution0.65%35,778
9,008Institution0.42%23,078
7,773Institution0.36%19,914
848Institution0.04%2,173

Top ETF Holders

Currently, No Data Available
Holder
# of Shares
Type
% Holding
Value

FAQ

Who Owns MyMD Pharmaceuticals (GB:0A8D)?
Currently, no data Available
What percentage of MyMD Pharmaceuticals (GB:0A8D) stock is held by institutional investors?
Currently, no data Available
What percentage of MyMD Pharmaceuticals (GB:0A8D) stock is held by retail investors?
Currently, no data Available
Who owns the most shares of MyMD Pharmaceuticals (GB:0A8D)?
Thomas A Nicolette owns the most shares of MyMD Pharmaceuticals (GB:0A8D).
    What is the significance of the ownership structure for a publicly traded company?
    The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
      What's Included in PREMIUM?
      Make informed decisions based on Top Analysts' activity
      Know what industry insiders are buying
      Get actionable alerts from top Wall Street Analysts
      Find out before anyone else which stock is going to shoot up
      Get powerful stock screeners & detailed portfolio analysis